Mindpeak
Category: AI in Healthcare
AI-powered digital pathology company transforming tissue analysis for cancer diagnostics and biomarker discovery Mindpeak was founded in 2018. The company is led by Felix Faber. Based in Hamburg, Germany. Team size: 11-50. Total funding raised: $18.3M. Latest round: Series A. Key investors include ZEISS Ventures, InnoVentureFund (IFB Innovationsstarter), AI.FUND, European Innovation Council (EIC) Fund, APEX Ventures, Nina Capital, Motu Ventures, Innovationsstarter Fonds Hamburg (IFH), Geratherm Medical AG.
- Founded
- 2018
- Headquarters
- Hamburg, Germany
- Team size
- 11-50
- Total funding
- $18.3M
Value proposition
AI-powered digital pathology platform that automates tissue analysis for cancer diagnostics, enabling pathologists to achieve faster, more accurate and reproducible diagnoses while unlocking predictive biomarkers invisible to the human eye
Products and solutions
peakDx (diagnostic AI), peakDissect (tissue dissection AI), peakDiscover (biomarker discovery), peakPredict (predictive AI), peakDeploy (deployment platform), peakAcademy (training), Phenoscout AI, Breast Suite, PD-L1 Suite, HER2 Suite
Unique value
Patented Pathology Frontier Model combining semi-supervised and supervised deep learning; zero-click workflow that pre-processes entire slides before pathologist opens the case; first German company with CE-IVD mark for AI in clinical routine pathology; 11 CE-IVD certified products
Target customer
Clinical pathology labs, diagnostic laboratories, biopharma companies (drug and biomarker discovery), hospitals
Industries served
Digital Pathology, Oncology, Precision Medicine, Biopharma R&D, Clinical Diagnostics
Technology advantage
Patented hybrid deep learning approach (semi-supervised + supervised); Pathology Frontier Model foundation model; zero-click workflow; explainable AI showing decision rationale; CE-IVD certified products in clinical use; multi-modal analysis (H&E, IHC, mIF)
How they differentiate
First-mover with CE-IVD certification in Germany (May 2021); patented hybrid deep learning approach; zero-click workflow that pre-processes all cells before pathologist opens case; explainable AI showing decision rationale; 11 CE-IVD products; strong biopharma customer base alongside clinical labs
Main competitors
Paige, Visiopharm, Aiosyn, PathAI
Key partnerships
Leica Biosystems (global reseller agreement, March 2026), ZEISS (investor and strategic partner), PathGroup (US pathology provider collaboration), Unilabs (European diagnostics provider, clinical deployment), Epredia (EU distribution agreement, February 2026), Discovery Life Sciences (AI precision biomarker testing partnership, March 2026), PathAI (AI products available via AISight Dx IMS, September 2025), AstraZeneca (HER2 AI diagnostics collaboration, 2025), Tubulis (strategic collaboration, December 2025)
Notable customers
Unilabs (one of largest European diagnostics providers), PathGroup (US premier pathology services provider), AstraZeneca (collaboration on HER2 AI diagnostics), Discovery Life Sciences (biomarker testing partnership), Tubulis (strategic collaboration on cancer innovation)
Major milestones
2018: Company founded, 2019: $3M seed round, May 2021: First CE-IVD mark for AI in clinical routine pathology in Germany, 2022: Released 10 CE-IVD marked products, entered biopharma market, 1600% revenue increase, Sep 2024: $15.3M Series A led by ZEISS Ventures and InnoVentureFund, Sep 2025: Partnership with PathAI for AISight Dx integration, Dec 2025: First patent granted across 18 EU states and UK, Dec 2025: Strategic collaboration with Tubulis, Feb 2026: EU distribution agreement with Epredia, Mar 2026: Global reseller agreement with Leica Biosystems
Growth metrics
1600% revenue increase in 2022; 90% reduction in diagnosis time reported by Unilabs; 11 CE-IVD certified products; over two-thirds of revenue from US market
Market positioning
Global frontrunner in AI-powered digital pathology with CE-IVD certified products already in clinical routine use across EU and US; among first AI pathology companies deployed in routine clinical diagnostics in both US and EU
Geographic focus
Global (headquarters in Hamburg, Germany; US office in Cambridge, MA; over two-thirds of revenue from US market)
Patents and IP
Granted patent across 18 EU member states and UK: 'Method for training an artificial intelligence system for recognising and classifying cells for pathological cell and tissue examination, classifying system, computer-readable medium' (Dec 2025)
About Felix Faber
Co-founded Bytro (online games company, IPO in 2015); Two-time world champion in robotic soccer with University of Freiburg; German Accelerator alumni in Silicon Valley; Studied Cognitive Science at University of Freiburg (2001-2004)
Latest news about Mindpeak
More AI in Healthcare companies
Official website: https://www.mindpeak.ai